Company news
Foresee Pharmaceuticals Co., Ltd. news in 2022
Foresee Pharmaceuticals Co., Ltd.'s news releases, calls and decks from 2022, newest first.
Foresee Pharmaceuticals will attend the investor conference held by Cathay Securities Corporation
August 15, 2022
The submission of an IND for FP-045 in patients with Fanconi anemia by TRPharm to the Ministry of Health of Turkey
August 10, 2022
Board of Directors resolved to approve the 2022Q2 consolidated financial report
August 8, 2022
Foresee Pharmaceuticals announces phase 2 results of FP-025 in patients with Covid-19 associated ARDS
August 2, 2022
The Submission of CAMCEVI 42 mg Marketing Authorization Application by Accord Healthcare, Foresee's Licensing Partner, to the MHRA of the UK
July 26, 2022
Foresee Pharmaceuticals announces the submission of a phase 3 IND to US FDA for FP-001 42 mg in patients with central precocious puberty
July 20, 2022
Foresee Pharmaceuticals announces the submission of New Drug Application for CAMCEVI 42 mg to TFDA
June 9, 2022
Foresee Pharmaceuticals announces EMA approval of CAMCEVI 42 mg for the treatment of advanced prostate cancer
May 30, 2022
Foresee Pharmaceuticals will attend the 11th Taiwan CEO Week held by Taiwan Stock Exchange and QIC
April 18, 2022
The submission of Marketing Authorization Application by Megapharm for CAMCEVI 42 mg to the Ministry of Health of Israel
April 5, 2022
CAMCEVI 42 mg Injection Emulsion launched in the U.S. for the Treatment of Advanced Prostate Cancer
April 4, 2022
Foresee Pharmaceuticals received positive CHMP opinion for CAMCEVI 42 mg for the treatment of advanced prostate cancer
March 24, 2022